ERBB2 and gastric cancer: To address this question, we used a bench-to-bedside approach, initially performing a high-throughput 1015 Exiqon miRCURY locked nucleic acid (LNA)TM microRNA inhibitor library screen in trastuzumab-treated HER2-positive NCI-N87 and HER2 negative FLO-1 oesophago-gastric cancer cell lines to shortlist candidate microRNAs that affect cell viability when treated with trastuzumab-based therapy.